[PEG-IFN-alpha(2a) 180 micro g once-weekly has enhanced pharmacokinetic and pharmacodynamic properties which translate into significantly improved efficacy and similar safety and tolerability compared with IFN-alpha in patients with chronic hepatitis C even with underlying cirrhosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
Gene-disease associations inferred from text-mining the literature.
DisGeNET evidence - LITERATURE